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ABSTRACT: The use of molecular simulation to estimate the
strength of macromolecular binding free energies is becoming
increasingly widespread, with goals ranging from lead
optimization and enrichment in drug discovery to person-
alizing or stratifying treatment regimes. In order to realize the
potential of such approaches to predict new results, not merely
to explain previous experimental ﬁndings, it is necessary that
the methods used are reliable and accurate, and that their
limitations are thoroughly understood. However, the computa-
tional cost of atomistic simulation techniques such as molecular dynamics (MD) has meant that until recently little work has
focused on validating and verifying the available free energy methodologies, with the consequence that many of the results
published in the literature are not reproducible. Here, we present a detailed analysis of two of the most popular approximate
methods for calculating binding free energies from molecular simulations, molecular mechanics Poisson−Boltzmann surface area
(MMPBSA) and molecular mechanics generalized Born surface area (MMGBSA), applied to the nine FDA-approved HIV-1
protease inhibitors. Our results show that the values obtained from replica simulations of the same protease−drug complex,
diﬀering only in initially assigned atom velocities, can vary by as much as 10 kcal mol−1, which is greater than the diﬀerence
between the best and worst binding inhibitors under investigation. Despite this, analysis of ensembles of simulations producing
50 trajectories of 4 ns duration leads to well converged free energy estimates. For seven inhibitors, we ﬁnd that with correctly
converged normal mode estimates of the conﬁgurational entropy, we can correctly distinguish inhibitors in agreement with
experimental data for both the MMPBSA and MMGBSA methods and thus have the ability to rank the eﬃcacy of binding of this
selection of drugs to the protease (no account is made for free energy penalties associated with protein distortion leading to the
over estimation of the binding strength of the two largest inhibitors ritonavir and atazanavir). We obtain improved rankings and
estimates of the relative binding strengths of the drugs by using a novel combination of MMPBSA/MMGBSA with normal mode
entropy estimates and the free energy of association calculated directly from simulation trajectories. Our work provides a
thorough assessment of what is required to produce converged and hence reliable free energies for protein−ligand binding.
1. INTRODUCTION
In the past two decades, both computationally assisted rational
drug design and personalized medicine have been held out as
potential new paradigms which would produce novel therapies at
a time when the approval of new drugs is in seemingly irreversible
decline.1,2 One of the key components of these approaches is the
need for predictive modeling of protein function and binding
selectivity. Consequently, delivering on the promises made for
each requires that the tools used in basic research are fully
validated and their range of applicability both understood and
acknowledged.
From a physical perspective, the quantity which governs
biomolecular association, determining whether proteins bind to
one another or ligands (where the latter may be natural or
pharmaceutical in origin), is the binding aﬃnity. Consequently,
the calculation of binding free energies (also known as “binding
aﬃnities”) is one of the most important areas of biomolecular
simulation. One of the most widely applied simulation
techniques in this ﬁeld is molecular dynamics (MD),3,4 in
which the motions of the atoms that make up proteins are
computed using a simpliﬁed model based on Newtonian
mechanics. Theoretically, the accuracy of the estimates of any
thermodynamic quantity fromMD is limited by two factors: that
of the force ﬁelds used to describe the interatomic interactions
and the inability to sample suﬃciently the ensemble of
microstates available to the system.
A variety of approaches are available for calculating binding
aﬃnities from MD simulations ranging from the theoretically
rigorous, such as thermodynamic integration (TI)5 or free energy
perturbation (FEP),6 to the largely empirical, such as the linear
interaction energy (LIE)7 method (excellent reviews of this
subject are available by Gilson and Zhou8 as well as Steinbrecher
and Labahn9). The computational requirements of these
methods tend to increase considerably as more physical detail
is included in the models used. In both drug discovery, where
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large numbers of candidates must be assessed, and clinical
applications, where diagnoses must typically be given in days or
at most weeks, rapid turnaround of calculations is vital, and
calculations that take a week or more to complete are unlikely to
ever be adopted beyond basic research environments.2 More
fundamentally, it is not the notional accuracy of the diﬀerent
methods but the reproducibility of the results obtained which
needs to be veriﬁed and validated before any method can be seen
as a reliable tool for future applications.
The molecular mechanics Poisson−Boltzmann surface area
(MMPBSA)10,11 and molecular mechanics generalized Born
surface area (MMGBSA)12 methods of estimating binding free
energies have become some of the most widely applied due to
their claims to provide a compromise between accuracy and
speed. Both of these methods, however, neglect to account for
changes in conﬁgurational entropy upon binding. Consequently,
they are frequently combined with estimates of this contribution
made using normal-mode analysis of harmonic frequencies from
minimized snapshots from the MD trajectory. While the
convergence and applicability of MMPBSA and MMGBSA
have been widely studied13,14 the computational cost of normal-
mode analysis has meant that only recently has its performance
begun to be similarly investigated.15 Here, we present an
extensive analysis of the convergence properties and ability to
reproduce experimental values of the methods applied to HIV-1
protease binding to the nine FDA-approved inhibitors. These
results build on our previous work that used these techniques to
evaluate diﬀerences in binding strength of diﬀerent protein
sequences to individual drugs in both the HIV protease16,17 and
the anticancer therapy target epidermal growth factor receptor
(EGFR).18 In the latter case, the prediction made for the L858R
mutant was thought to disagree with experimental results,19 but
more recent data have conﬁrmed the validity of the computa-
tional estimates.20
Ensembles of multiple short simulations were run for each
protein−ligand combination, as previous studies have suggested
that a multiple/ensemble MD approach can sample phase space
more eﬃciently than fewer long time simulations.16,21,22 This
approach also allows us to investigate the reproducibility of the
calculations on the individual simulations within an ensemble
(we will refer to an individual simulation within an ensemble for
each inhibitor as a replica). We also evaluate the performance of a
signiﬁcantly less computationally expensive method proposed by
Swanson et al.23 for accounting for neglected terms in the
MMPBSA/MMGBSA methods using the MD trajectories
directly. As part of this investigation, we have looked at
combining this contribution with MMPBSA/MMGBSA calcu-
lations alone as well as the novel combination of these two
components with normal mode derived entropy estimates.
2. METHODS
When two reactants combine at constant temperature and
pressure, the binding aﬃnity is characterized by the change in
Gibbs free energy given by
Δ = Δ − ΔG H T S (1)
at temperature T and is composed of the change in enthalpy
(ΔH) and the change in entropy (ΔS). In this study, we aim to
assess the ability of several diﬀerent end-point free energy
calculation methodologies to estimate ΔG using protein−ligand
conformations generated via molecular dynamics simulations.
The methods under investigation are MMPBSA10,11 and
MMGBSA,12 including and excluding terms aiming to explicitly
incorporate solute entropic contributions to the binding energy.
All of these methods run as post-processing steps on snapshots
taken from the MD trajectories, with averages computed over all
snapshots.
Even when incorporating terms describing solute entropic
contributions, these methods possess several apparent limita-
tions for computing absolute binding free energies. They do not
implicitly account for free energy diﬀerences that arise from
possible changes in key protonation states or explicit water-
mediated binding between a protein and ligand which may
provide signiﬁcant contributions to the binding free energy.24
Despite these limitations and scepticism about the validity of the
methods in some quarters,25 our previous work indicates that
changes in binding energy of less than 1 kcal mol−1 betweenHIV-
1 protease mutants can be distinguished.16,26
2.1. Free Energy Calculation Protocols. Both MMPBSA
and MMGBSA are end-point free-energy calculations. In such
methods, the free energy of binding, ΔG, is calculated using
Δ = ⟨ ⟩ − ⟨ ⟩ − ⟨ ⟩G G G Gcomplex enzyme ligand (2)
where ⟨Gcomplex⟩, ⟨Genzyme⟩, and ⟨Gligand⟩ are the average values of
the Gibbs free energy for the complex, enzyme, and ligand,
respectively. Separate simulation of the complex and its two
components can be used, but due to diﬃculties in obtaining
converged free energies, it is more common to extract
conﬁgurations of the free enzyme and ligand from simulation
of the complex. Much of the improved convergence behavior of
the single trajectory approach is due to the fact that the noisy
term describing the internal energy of the system components is
canceled between ligand, enzyme, and complex.13 This is the
strategy we have employed in the present study. Normal mode
solute entropy calculations use the same conﬁgurations and also a
calculation similar to eq 2 to calculate the overall entropic penalty
from values computed for the complex, enzyme, and ligand. The
free energy of association, however, deals exclusively with the
degrees of freedom available to the bound ligand and is
computed from collections of snapshots. The details of all four
computations are provided below.
2.1.1. MMPBSA and MMGBSA. The binding free energy
change calculated by MMPBSA and MMGBSA (ΔGMMPB(GB)SA)
can be broken down into a number of components:
Δ = Δ + Δ + Δ + Δ
+ Δ
G G G G G
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MM
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MM
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MM
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sol
(3)
where ΔGvdWMM and ΔGeleMM are the van der Waals and electrostatic
contributions to the molecular mechanics free energy diﬀerence,
respectively, and ΔGpolsol and ΔGnonpolsol are the polar and nonpolar
solvation terms, respectively. Modules of the AMBER 9
package27 were used in the evaluation of all components of the
MMPBSA calculation. The SANDER module was employed to
calculate both molecular mechanics terms (ΔGvdWMM and ΔGeleMM),
with no cutoﬀ being applied to the nonbonded energies. The
electrostatic free energy of solvation, ΔGpolsol , is the part of the
calculation described by the Poisson−Boltzmann (PB) or
generalized Born (GB) calculation. GB is an approximation to
PB, and in both methods internal and external dielectric
constants of 1 and 80, respectively, were used. In the PB case,
a thousand iterations of the linear Poisson−Boltzmann equation
were performed on a cubic lattice grid with a spacing of 0.5 Å
using the DelPhi28 program. The GB calculations were calculated
using the model proposed by Onufriev al.12 The nonpolar
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solvation energy, ΔGnonpolsol , was calculated from the solvent
accessible surface area (SASA) using the MSMS program29 with
a 1.4 Å radius probe based on the equation:
γ βΔ = +G Anonpolsol (4)
where A is the solvent accessible surface area diﬀerence, γ is the
surface tension, and β is the oﬀset. The constants γ and βwere set
to the standard values of 0.0052 kcal mol−1 Å−2 and 0.92 kcal
mol−1, respectively, in ourMMPBSA simulations and 0.0072 kcal
mol−1 Å−2 and 0 kcal mol−1 in MMGBSA.10−12
2.1.2. NormalMode Analysis.The nonpolar solvation term of
the MM(GB)PBSA calculation incorporates an implicit estimate
of the entropic changes associated with the insertion of a solute
into the solvent. However, no account is made for the entropic
impact of changes in the conﬁgurational freedom of the enzyme
and ligand upon complex formation in vacuo. In general,
protein−ligand binding events cause restrictions to the number
of conformations available to both and consequently a reduction
in entropy; this contribution is known as the conﬁgurational (or
conformational) entropy. For some systems, it has been observed
that agreement with experimental binding aﬃnity values can be
improved by incorporating a normal mode estimation of the
entropic component of the binding free energy alongside
MMPB(GB)SA.16,30 Including this contribution, the ﬁnal
binding aﬃnity estimate ΔGtheor is given by
Δ = Δ − Δ−G G T Stheor PB(GB) MMPB(GB)SA NM (5)
where ΔGMMPB(GB)SA is the MMPBSA or MMGBSA binding
aﬃnity estimate, T is the thermodynamic temperature, and
−TΔSNM is the normal mode estimate of the conﬁgurational
entropy penalty of the binding reaction.
As implemented within the AMBER 9 package27 employed in
this study, ΔSNM is the combination of three components:
Δ = Δ + Δ + ΔS S S SNM tra rot vib (6)
where ΔStra, ΔSrot, and ΔSvib are the contributions related to
changes in translational, rotational, and vibrational freedoms,
respectively.
2.1.3. Free Energy of Association. Swanson et al.23 proposed
a method for improving the validity of MMPBSA binding energy
calculations which they called the free energy of association
(which we will denote usingΔGAssoc); this is simply added to the
MMPB(GB)SA value:
Δ = Δ + Δ−G G GPB(GB) Assoc MMPB(GB)SA Assoc (7)
ΔGAssoc is conceptually linked to the freedom of motion which is
left to the ligand upon binding and provides a previously lacking
link between the estimated binding aﬃnity and the standard
concentration. Swanson et al.23 assumed that other contributions
to the conformational entropy change upon binding were
negligible. They also note that the validity and accuracy of normal
mode calculations of conﬁgurational entropy remain question-
able. However, ΔGAssoc may be conceived of as an alternative
approach to compute the ΔStra and ΔSrot contributions to the
free energy. In this work, we have investigated not only
ΔGPB(GB)−Assoc but also a calculation of the binding free energy
incorporating ΔGAssoc and ΔSvib:
Δ = Δ + Δ − ΔG G G T SPB(GB)AssocNM MMPB(GB)SA Assoc vib
(8)
ΔGAssoc is computed from
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whereCo is the standard state concentration, usually taken to be 1
M (1 molecule/1660 Å3), zlig
trans and zlig
rot are the ligand
translational and rotational conﬁguration integrals, respectively.
zlig
trans was calculated by superimposing every snapshot onto an
average structure of the protease using Cα atoms alone. This
provides a static reference system along with an average ligand
structure. The eigenvalues (λi) of the covariance matrix of the
ligand center of mass were then computed providing variance
measures along three independent axes from the relation λi =
⟨Δxi2⟩. The translational conﬁgurational integral is then given by
π= ⟨Δ ⟩⟨Δ ⟩⟨Δ ⟩z x x x(2 ) ( )ligtrans 3/2 12 22 32 1/2 (10)
Similarly, the ligand’s rotational integral can be computed
from quaternions representing the ligand’s rotational motion
relative to the average structure. A small angle approximation
allows the reduction of the three quaternions describing rotation
about three axes into a single quaternion, three of whose
components are sinusoidally related to three rotation angles. As
for the translational component, the covariance matrix can be
evaluated to produce eigenvalues that can be used to calculate zlig
rot
in an analogous manner to eq 10.
The structural superposition of each snapshot onto the average
structure was performed using scripts based on the alignment
code found in MDAnalysis.31−33 The use of this method is
attractive as it is based on the conﬁgurations taken directly from
the simulations and is computationally inexpensive. This method
assumes that the simulation explores a single minimum, whereas
we expect that replicas will explore diﬀerent minima.
Consequently, here we evaluate ΔGAssoc for each replica
individually.
2.2. Model Preparation and Simulation Protocol.
Preparation and simulation setup were performed using the
automated Binding Aﬃnity Calculator (BAC); full details of this
tool and the simulation parameters employed are available in
Sadiq et al.34 Models of the subtype B HXB2 wildtype sequence
of HIV-1 were constructed using the coordinates from PDB
crystal structures listed in Table 1. All systems were solvated in
orthorhombic water boxes with a minimum extension from the
protein of 14 Å.
Protein parameters were taken from the standard AMBER
force ﬁeld for bioorganic systems (ﬀ03).35 Drug parameters were
produced using the general AMBER force ﬁeld (GAFF)36
following the procedure detailed in Sadiq et al.34 with the
Table 1. The PDB Codes of the Crystal Structures Used to
Provide Coordinates for theHIV-1 Protease Bound to Each of
the Nine FDA-Approved Protease Inhibitors
drug name abbreviation PDB
Amprenavir APV 1HPV
Atazanavir AZV 2AQU
Darunavir DRV 2HSI
Indinavir IDV 1HSG
Lopinavir LPV 1MUI
Nelﬁnavir NFV 1OHR
Ritonavir RTV 1HXW
Saquinavir SQV 1FB7
Tipranavir TPV 2O4P
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exception that drug protonation states were determined using
Open Babel37 (using a pH of 5, based upon the conditions used
in most binding assays for the protease). Gaussian 9838 was used
to perform geometric optimization of the inhibitor with 6-31G**
basis functions, and the restrained electrostatic potential (RESP)
procedure, also part of the AMBER package, was used to
calculate the partial atomic charges. All ligands were found to be
neutral except for Indinavir, which was protonated at pH 5, in
agreement with the previous ﬁndings of Oehme et al.15
(structures for all nine inhibitors are shown in Figure 1). Before
the production simulations reported here were run, all systems
were minimized and equilibrated for 2 ns using the protocol
deﬁned by the BAC.34
All simulations presented here were performed in the
molecular dynamics package NAMD239 in the NPT ensemble
with a temperature of 300 K and a pressure of 1 bar, using a 2 fs
time step. Free energy analysis was conducted on conﬁguration
snapshots generated over the course ofMD simulations using the
NMODE and MMPBSA modules of the AMBER 9 package.27
Snapshots were output every 10 ps to give 100 snapshots per
nanosecond of simulation. Management of ensemble simulation
runs and analysis was facilitated by use of the BigJob40,41
extension of the SAGAmiddleware,42 further details of which are
provided in Supporting Information.
The HIV-1 protease consists of two peptide chains, which are
usually constructed from the same sequence of amino acids (the
structure of the drug bound protein is shown in Figure 2). The
catalytic function of the enzyme is performed by a dyad which
consists of two aspartic acid (Asp) residues, one in position 25 of
each chain (we label that in the ﬁrst chain D25 and that in the
second D25′). It has been established by our group and others
that the correct determination of the protonation state of the
catalytic dyad of HIV-1 protease is of vital importance in order to
obtain accurate binding aﬃnities.16,43 Four possible protonation
states are possible for the system: dianionic (D−), diprotonated
(D25, D25′), Asp 25 protonated (D25), and Asp 25′ protonated
(D25′). We have employed the same protocol used previously to
establish the protonation state appropriate for lopinavir (LPV)16
in order to ascertain the correct protonation state for each drug.
Twenty replica simulations (varying only in having diﬀerent,
randomized initial velocities) were performed for each system.
Each simulation produced 2 ns of equilibration and 4 ns of
production trajectory. In all cases except Tipranavir, where the
diprotonated system was favored, the protein was found to be
monoprotonated. Full results for each system are given in Table
S1.
Once the correct catalytic dyad protonation state was
determined for each drug, 30 more replicas were performed for
all systems using the same conditions and the binding aﬃnity
averages calculated from the full 50 member ensembles used for
our ﬁnal comparison of drug binding aﬃnities. This size of
ensemble was shown to provide well converged ΔGMMPBSA
results for protease mutants bound to the inhibitor lopinavir in
our previous work.16 A second ensemble of the lopinavir system
was run and analyzed in order to assess the reproducibility of the
Figure 1. The chemical structures of all nine FDA-approved protease inhibitors simulated in this study.
Figure 2. Structure of the lopinavir bound HIV-1 protease (shown in
cartoon representation). The two monomers are shown in white and
gray, with the inhibitor lopinavir and the catalytic dyad at position 25 of
each protease monomer in chemical structure representation (in red and
orange, respectively). The conserved water molecule bound between
the inhibitor and protease ﬂaps is shown in blue.
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binding aﬃnity estimates produced (the second ensemble is
denoted as LPV 2).
3. RESULTS
Our aim in the following sections is to investigate both the level
of conformational sampling required to obtain converged results
and, once this has been ascertained, to compare the performance
of the diﬀerent methods of free energy calculation in terms of
how well they reproduce experimental results.
3.1. Internal Sampling, Convergence, and Reproduci-
bility. The combination of the computational cost of the
calculations and the necessity for rapid results in applications
such as drug discovery and lead enrichment has led many
previous studies of MMPBSA and MMGBSA performance to be
limited to single simulations, often providing less than 10 ns of
MD trajectory for analysis.13−15 Here, we use ensembles of 50
simulations to determine the variability of the results produced
by these analyses and how they depend upon the replica length
and rate at which conformational samples are taken from theMD
trajectories. This strategy is enabled by the increasing availability
of supercomputing resources with many thousands of cores
(sometimes referred to as petascale resources) which make the
execution of many large simulations feasible. In this work, we
harnessed resources on both the U.S. XSEDE and E.U. PRACE
networks (details of the machines used can be found in the
Supporting Information).
3.1.1. Eﬀect of Simulation Length and Sampling Rate. Our
previous work indicated that ensembles of 50 replica simulations
producing 4 ns of production trajectory were capable of
producing well converged MMPBSA values and correctly
ranking a series of protease mutants bound to lopinavir (LPV)
but that longer single simulations could not.16 More recent work
has suggested that single simulations of 10 ns duration can
produce reliable results using MMPBSA for a selection of 14
HIV-1 protease inhibitors selected to give a wide range of
aﬃnities and to include representatives of six diﬀerent scaﬀolds
identiﬁed from the literature14 Here, we focus on using 50 replica
ensembles to see if we can extend our previous analysis to cover
all of the FDA approved HIV-1 protease inhibitors. In order to
assess the impact of replica simulation length and sampling rate
on the convergence of averages obtained by each of the free
energy protocols under study, a method to quantify the error in
the averages taken from a given ensemble is required. We have
chosen to use the statistical technique of bootstrapping.44 This
method involves resampling with replacement the N input data
points (in this case, the snapshot values of ΔGMMPBSA,
ΔGMMGBSA, or −TΔSNM) to provide a new bootstrap sample
also containing N data points. This process is repeated many
times (in our case 10 000 times) and the mean of each bootstrap
population calculated. The standard deviation (σboot) of these
means provides an estimate of the error associated with an
average derived from a given sample.
Figure 3 shows the variation of σboot with replica length and
sampling rate for ΔGMMPBSA, ΔGMMGBSA, and −TΔSNM in the
case of the wildtype protease bound to lopinavir (LPV). The
most surprising feature of these tracks is that after 4 ns, σboot
increases for both ΔGMMPBSA and ΔGMMGBSA despite the
increased level of sampling being used. This is particularly
pronounced forΔGMMPBSA and is due to the ingress of water into
the active site as identiﬁed in our previous work,16,17,45 leading to
higher variability in MMPBSA results. This may also explain a
slight drift in binding strength observed in the nanosecond
average values over time, see Figure S1. The results for
ΔGMMGBSA already appear very well converged at the 4 ns
point with a σboot of less than 0.21 kcal mol
−1 at all of the sampling
rates investigated; in the case of ΔGMMPBSA, the error is less than
0.3 kcal mol−1 at this trajectory length. We have therefore limited
all of the remaining replica lengths to 4 ns. There is little beneﬁt
observable for either method when the sampling rate is increased
above 20 snapshots per nanosecond. Despite this, for reasons of
consistency with our previous work, we have used 100 snapshots
per nanosecond for our ΔGMMPBSA and ΔGMMGBSA averages.
Analysis of the convergence of the separate components of
ΔGMMPBSA and ΔGMMGBSA can be found in the Supporting
Information.
Figure 3. The variation of the bootstrap statistics, σboot, with replica
simulation length and the sampling rate used for the averages of (a)
ΔGMMPBSA, (b) ΔGMMGBSA, and (c) −TΔSNM for 50 replica ensemble
simulations of wildtype HIV-1 protease bound to the inhibitor LPV.
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Figure 3c shows that, unlike for ΔGMMPBSA, the error on
−TΔSNM averages is signiﬁcantly reduced as the sampling rate
increases up to a maximum of 100 snapshots per nanosecond.
Here, there is no sign of any change in the convergence behavior
as the length of simulation produced by each replica is increased.
In order to have comparable error levels at reasonable
computational cost, we have chosen to use 25 snapshots per
nanosecond for −TΔSNM calculations which provide an
estimated error σboot of approximately 0.3 kcal mol
−1, comparable
to those obtained for ΔGMMPBSA.
3.1.2. Variance Between Replicas. Given that the vast
majority of publications that apply the MMPBSA or MMGBSA
methodologies report no more than one or two simulations, it is
instructive to examine the variation in binding free energy values
that we observe from diﬀerent replica simulations. Figure 4a,c
show the distribution of the averages obtained for each replica via
the MMPBSA and MMGBSA methodologies, respectively. The
distributions are very broad for all combinations of drug and
methodology, in almost every case (excepting NFV using
MMGBSA and one of the LPV replicas using MMPBSA) the
range of values observed being greater than 7 kcal mol−1. Using
both methodologies, the values for AZV and RTV have the
largest ranges, all of which exceed 10 kcal mol−1. In addition to
the width of these distributions it is clear from visual inspection
that the results do not ﬁt well to the expected Gaussian
distribution, which would seem to indicate that sampling on this
level is not well converged. By contrast, the ΔGMMPBSA and
ΔGMMGBSA snapshot distributions, shown in Figure 4b and d,
respectively, do appear to follow well-deﬁned Gaussian
distributions. We suggest that the latter observation and the
fact that the distributions for the two LPV replicas lie very close
Figure 4. Normalized frequency distribution analysis of the binding aﬃnities. Distributions for MMPBSA (ΔGMMPBSA) are shown in (a) per replica
averages and (b) per snapshot and those for MMGBSA (ΔGMMGBSA) in (c) per replica average and (d) per snapshot for each of the nine protease
inhibitors studied. In the case of the inhibitor lopinavir (LPV), two replica ensembles are shown, the ﬁrst with open circles and the latter with ﬁlled
triangles. Explanations of the abbreviations used for each drug are given in Table 1. The expected normal distribution given the same mean and standard
deviation for each data set is shown by the blue lines (the distribution for the second LPV replica is shown in red).
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together mean that the overall averages are well converged, even
if this is not clear from the replica distributions.
A similar result is obtained for normal mode estimates of the
conﬁgurational entropy, albeit with a much larger range in the
snapshot values obtained. Again, the snapshot based normalized
frequency distributions of the values closely resemble normal
distributions with the same mean and standard deviation as
shown in Figure 5b. This is a signiﬁcant result as, previously, we
were unable to obtain the expected Gaussian distribution of
values when using a lower sampling rate of ﬁve snapshots per
nanosecond for a total of 1000 snapshots per ensemble (here, we
use 5000).16 The computational cost of normal-mode analysis
has meant that many published studies use far fewer snapshots
than this. In all cases, the distributions are very broad, the range
of values is greater than 80 kcal mol−1, and the distributions
encompass some snapshots with attractive (negative) contribu-
tions to the binding free energy. As for the MMPB(GB)SA
results, the replica averages do not produce well-deﬁned normal
distributions. However, in line with the bootstrap analysis
presented above, the replica distributions are only seen to be as
Figure 5.Normalized frequency distribution analysis of the conformational entropy contribution to the binding aﬃnities (−TΔSNM) calculated for (a)
each replica and (b) each conﬁgurational snapshot computed using normal-mode analysis for each of the nine protease inhibitors studied. In the case of
the inhibitor lopinavir (LPV), two replica ensembles are shown, the ﬁrst with open circles and the latter with ﬁlled triangles. Explanations of the
abbreviations used for each drug are given in Table 1. The expected normal distribution given the same mean and standard deviation for each data set is
shown by the blue lines (the distribution for the second LPV replica is shown in red).
Figure 6.Normalized frequency distribution analysis of the binding aﬃnities calculated for each replica using (a) MMPBSA and normal-mode analysis
(ΔGtheor−PB) and (b) MMGBSA and normal-mode analysis (ΔGtheor−GB) for each of the nine protease inhibitors studied. In the case of the inhibitor
lopinavir (LPV), two replica ensembles are shown, the ﬁrst with open circles and the latter ﬁlled triangles. The narrowest replica distributions for the
ΔGMMPBSA and ΔGMMGBSA results (for NFV and LPV, respectively) are 1.5 and 1.6 kcal mol−1. The expected normal distribution given the same mean
and standard deviation for each data set is shown by the blue lines (the distribution for the second LPV replica is shown in red).
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broadly distributed as those for the MMPB(GB)SA results. This
conﬁrms that by using 25 snapshots per replica we are able to
produce well converged estimates of the conﬁgurational entropy.
Analysis of the three contributions to −TΔSNM indicates that all
of the variation observed in the overall computation comes from
−TΔSvib and consequently that the discussion above applies
equally to this component of ΔGPBAssocNM and ΔGGBAssocNM.
It is not possible to produce consistent per snapshot
distributions of ΔGtheor−PB or ΔGtheor−GB, due to the diﬀerences
in sampling rate, but per replica distributions show similar
deviations and have a comparable range to those of ΔGMMPBSA
and ΔGMMGBSA (see Figure 6). The narrowest replica
distributions for the ΔGMMPBSA and ΔGMMGBSA results (for
NFV and LPV, respectively) have a standard deviation of 1.5 and
1.6 kcal mol−1, while those for ΔGtheor−PB and ΔGtheor−GB (TPV
and LPV, respectively) are 2.22 and 2.48 kcal mol−1. The two
largest drugs under investigation, RTV and AZV, have
consistently broader distributions than the others using either
MMPBSA or MMGBSA, with or without the incorporation of
−TΔSNM.
Unlike MMPB(GB)SA and normal modes, the binding free
energy of association, ΔGAssoc, has not previously been widely
applied, and little is known about the performance of this
methodology. Figure 7 shows that we obtain comparatively
narrow distributions of the replica averages compared to any of
the other free energy components studied here, with a typical
range of approximately 5 kcal mol−1. The overall averages also
show a relatively small range across the diﬀerent drugs of only
4.29 kcal mol−1 with six of the nine drugs having averages
between 11 and 12 kcal mol−1 (further details are provided in
Table S4). It does not appear from the distributions thatΔGAssoc
is well converged for the ensembles used here, suggesting that for
this technique more sampling is required. An alternative
explanation of the poor approximation to a normal distribution
is that the naive implementation of this technique applied here
(assuming that each replica represents a single local energy
minimum) is inappropriate and that some form of clustering
might be used before the calculation is performed.
Overall, the results presented here conﬁrm the observation
that individual simulation trajectories do not yield reproducible
results but that ensembles of simulations can be eﬃciently used
to generate converged free energy estimates. Thus, our ﬁndings
made previously about lopinavir bound to protease sequences of
diﬀerent binding strengths16 also apply in the case of the ranking
of diﬀerent protease inhibitors. Remarkably, we observe that the
distribution of replica averages of −TΔSNM is no broader than
that of ΔGMMPBSA or ΔGMMGBSA. Bootstrap analysis of the
number of replicas indicates that an ensemble size of 50
represents a good compromise between computational eﬀort and
the accuracy of the sampling obtained (see Figure S3).
3.2. Comparison with Experimental Data. In order to
assess the eﬃcacy of the binding aﬃnity assessment method-
ologies we have employed, it is necessary to compare our results
with experimental values. We searched BindingDB,46 an online
database of measured binding aﬃnities, to identify data sets
which covered all nine FDA-approved protease inhibitors under
comparable experimental conditions. We found data sets from
two groups that ﬁt these criteria, reported by Freire and co-
workers47−49 (we will refer to this as Expt1) and by Dierynck et
al.50 (we will refer to this as Expt2). Two statistical measures are
often used to compare computationally derived binding
estimates to those from experiments; the coeﬃcient of
determination (r2) and the Spearman rank coeﬃcient (rs). The
former describes the level of linear correlation between the two
data sets, the latter whether the rank ordering of the two data sets
is the same. Comparing the two experimental data sets, we obtain
an r2 value of 0.47 and an rs of 0.90, suggesting that while the rank
ordering of the proteins is consistent the exact diﬀerences
between ligands varies considerably. Consequently, we decided
to use rs as the main metric to assess the performance of the
diﬀerent free energy methodologies we have employed and to
compare our results to both the two experimental data sets and
the average of the two (we will refer to the average data set as
ExptAvg).
None of the methodologies produce rs results higher than 0.63
for Expt1, Expt2, or ExptAvg (see Table 2). The methods
incorporating contributions of conﬁgurational entropy
(ΔGtheor−PB and ΔGtheor−GB) or the free energy of association
(ΔGPB−Assoc and ΔGGB−Assoc) alone generally slightly improve on
those that do not (ΔGMMPBSA and ΔGMMGBSA) but with the best
results coming from incorporating both (ΔGPBAssocNM and
ΔGGBAssocNM). Graphical comparisons of the computed binding
Figure 7. Normalized frequency distribution analysis of the free energy
of association (ΔGAssoc) for each replica. The expected normal
distribution given the same mean and standard deviation for each data
set is shown by the blue lines (the distribution for the second LPV
replica is shown in red).
Table 2. Spearman Rank Coeﬃcient (rs) for Each of the
Studied Computational Free Energy Methodologies
Compared to the Two Experimental Data Sets and Their
Average, Ranking All Nine FDA Approved Drugs
method Expt1 Expt2 ExptAvg
ΔGMMPBSA 0.57 0.41 0.48
ΔGMMGBSA 0.46 0.35 0.39
ΔGtheor−PB 0.56 0.43 0.56
ΔGtheor−GB 0.55 0.43 0.57
ΔGPB−Assoc 0.57 0.41 0.48
ΔGGB−Assoc 0.51 0.38 0.44
ΔGPBAssocNM 0.61 0.53 0.62
ΔGGBAssocNM 0.60 0.55 0.63
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aﬃnities and corresponding experimental values can be found in
the Supporting Information.
Table 3 details the comparison between free energy estimates
computed via MMPBSA (ΔGMMPBSA) and MMGBSA
(ΔGMMGBSA) alone and incorporating normal mode derived
conﬁgurational entropy (ΔGtheor−PB and ΔGtheor−GB). The only
values to approach accuracy in terms of the absolute binding free
energy are fromΔGtheor−PB. Even these values are generally more
positive (less attractive) than the experimental values; this is
consistent with previous observations that the binding of the
conserved water molecule contributes between 3 and 4 kcal
mol−1 to the strength of binding51−53 The observations regarding
the two larger ligands remain relevant upon inclusion of ΔGAssoc
alongside the vibrational component of the conﬁgurational
entropy (see Table 4). The values of ΔGPBAssocNM and
ΔGGBAssocNM do not reproduce the absolute experimental values
as well as ΔGtheor−PB.
The binding aﬃnity estimates for two drugs, those for RTV
and AZV, stand out as being much too attractive. It was noted
above that these two ligands exhibited the least well behaved
replica distributions for all of the free energy calculation
components and that they are the largest drugs in the data set.
It is likely that these drugs distort the protein geometry more
than is the case for smaller drugs and that there should be an
energetic penalty associated with this.54 The calculations
presented a single trajectory approach, and consequently no
account is taken of these potential contributions to the binding
aﬃnity (sometimes referred to as “strain”24). Speciﬁcally, these
larger drugs have more interactions outside the active site (in the
sites usually referred to as P3 and P3′ either side of the binding
cavity) than are found in other ligands.54 This region of the
protease is made up of residues R8 and P81 of one monomer and
G27, A28, D29, D30, G48, and G49 of the other. It is possible
that these interactions stabilize unrepresentative minima in the
free energy landscape close to the original crystal structure, which
may require additional sampling to escape from compared to
simulations of smaller ligands. We investigated the idea that
simply increasing the length of each replica might overcome any
such barriers by extending 10 replicas of the RTV ensemble to 20
ns and found that in one case a conformational ﬂip in the D29
residue allowed water access to the drug which was accompanied
by a weakening of ΔGMMPBSA estimates of binding strength of
approximately 10 to 15 kcal mol−1 (see Supporting Information).
Our previous work has shown that when RTV is docked into
protease conformations taken from LPV simulations, a
signiﬁcantly lower binding aﬃnity is obtained than in simulations
started fromRTV crystal structures45 (although not by enough to
result in a correct ranking with respect to the results obtained for
other inhibitors in this study). This phenomenon was observed
to be linked to the accessibility of the drug and protease active
site to individual water molecules. Oehme et al.15 have also
suggested that the binding strength of larger drugs is over-
estimated by MMPBSA and MMGBSA, although they did not
note any speciﬁc interactions as the cause.
Excluding the two larger drugs, we obtain much improved
rankings as shown in Table 5. Both the ΔGPBAssocNM and
Table 3. Binding Aﬃnity Estimates for All FDA-Approved HIV-1 Protease Inhibitors Bound to HXB2 Wildtype Proteasesa
drug ΔGMMPBSA ΔGMMGBSA −TΔSNM ΔGtheor−PB ΔGtheor−GB ΔGExpt1 ΔGExpt2 ΔGExptAvg
APV −41.81 (0.04) −55.54 (0.03) 32.96 (0.24) −8.85 (0.28) −22.58 (0.27) −13.2 (0.03) −12.3 (0.12) −12.7 (0.15)
AZV −54.06 (0.05) −66.22 (0.04) 35.48 (0.25) −18.59 (0.30) −30.74 (0.29) −14.2 (0.09) −12.7 (0.05) −13.4 (0.14)
DRV −47.38 (0.04) −63.39 (0.03) 31.97 (0.24) −15.41 (0.28) −31.42 (0.27) −15.0 (0.09) −16.6 (0.20) −15.8 (0.29)
IDV −42.16 (0.03) −61.19 (0.02) 37.02 (0.23) −5.14 (0.26) −24.17 (0.25) −12.4 (0.03) −11.7 (0.23) −12.1 (0.26)
LPV −47.68 (0.04) −64.40 (0.02) 37.31 (0.23) −10.37 (0.27) −27.09 (0.25) −15.1 (0.09) −13.0 (0.06) −14.1 (0.15)
LPV 2 −48.38 (0.03) −64.79 (0.03) 38.13 (0.24) −10.25 (0.27) −26.66 (0.27) −15.1 (0.09) −13.0 (0.06) −14.1 (0.15)
NFV −42.75 (0.03) −57.71 (0.02) 33.15 (0.24) −9.60 (0.27) −24.56 (0.26) −12.8 (0.05) −11.5 (0.21) −12.1 (0.26)
RTV −58.80 (0.03) −71.23 (0.03) 37.68 (0.24) −21.12 (0.27) −33.55 (0.27) −13.7 (0.05) −11.8 (0.10) −12.7 (0.15)
SQV −44.17 (0.04) −59.29 (0.03) 36.93 (0.24) −7.24 (0.28) −22.36 (0.27) −13.0 (0.04) −12.0 (0.13) −12.5 (0.17)
TPV −43.08 (0.03) −59.00 (0.03) 32.15 (0.24) −10.93 (0.27) −26.85 (0.27) −14.6 (0.09) −12.5 (0.22) −13.5 (0.31)
aValues are shown for MMPBSA (ΔGMMPBSA), MMGBSA (ΔGMMGBSA), normal mode derived conﬁgurational entropy (−TΔSNM), and combined
methods (ΔGtheor−PB and ΔGtheor−GB). Experimental values from Ohtaka et al.,47 Ohtaka and Freire,48 Velazquez-Campoy et al.,49 and Dierynck et
al.50 are also shown (denoted by Expt1, Expt2, and ExptAvg, respectively). Mean energies are in kcal mol−1. Standard errors are shown in
parentheses.
Table 4. Binding Aﬃnity Estimates for All FDA Approved HIV-1 Protease Inhibitors Bound to HXB2 Wildtype Proteasesa
drug ΔGMMPBSA ΔGMMGBSA ΔGAssoc −tδSVib ΔGPBAssocNM ΔGGBAssocNM ΔGExpt1 ΔGExpt2 ΔGExptAvg
Apv −41.81 (0.04) −55.54 (0.03) 11.14 (0.21) 8.33 (0.24) −22.34 (0.49) −36.07 (0.48) −13.2 (0.03) −12.3 (0.12) −12.7 (0.15)
Azv −54.06 (0.05) −66.22 (0.04) 12.68 (0.17) 9.98 (0.25) −31.40 (0.46) −43.56 (0.46) −14.2 (0.09) −12.7 (0.05) −13.4 (0.14)
Drv −47.38 (0.04) −63.39 (0.03) 11.18 (0.16) 7.16 (0.24) −29.04 (0.44) −45.05 (0.43) −15.0 (0.09) −16.6 (0.20) −15.8 (0.29)
Idv −42.16 (0.03) −61.19 (0.02) 10.68 (0.23) 11.75 (0.23) −19.73 (0.50) −38.76 (0.50) −12.4 (0.03) −11.7 (0.23) −12.1 (0.26)
Lpv −47.68 (0.04) −64.40 (0.02) 11.58 (0.16) 12.07 (0.23) −24.03 (0.43) −40.75 (0.41) −15.1 (0.09) −13.0 (0.06) −14.1 (0.15)
Lpv 2 −48.38 (0.03) −64.79 (0.03) 11.15 (0.14) 12.88 (0.24) −24.35 (0.41) −40.76 (0.41) −15.1 (0.09) −13.0 (0.06) −14.1 (0.15)
Nfv −42.75 (0.03) −57.71 (0.02) 14.23 (0.16) 8.25 (0.24) −20.27 (0.43) −35.23 (0.42) −12.8 (0.05) −11.5 (0.21) −12.1 (0.26)
Rtv −58.80 (0.03) −71.23 (0.03) 11.9 (0.17) 12.13 (0.24) −34.77 (0.44) −47.2 (0.44) −13.7 (0.05) −11.8 (0.10) −12.7 (0.15)
Sqv −44.17 (0.04) −59.29 (0.03) 9.94 (0.19) 11.53 (0.24) −22.7 (0.47) −37.82 (0.46) −13.0 (0.04) −12.0 (0.13) −12.5 (0.17)
Tpv −43.08 (0.03) −59.00 (0.03) 11.86 (0.13) 6.97 (0.24) −24.25 (0.41) −40.17 (0.39) −14.6 (0.09) −12.5 (0.22) −13.5 (0.31)
aValues are shown for MMPBSA (ΔGMMPBSA), MMGBSA (ΔGMMGBSA), the free energy of association (ΔGAssoc), the vibrational component of the
normal mode derived conﬁgurational entropy (−TΔSvib), and combined methods (ΔGPBAssocNM and ΔGGBAssocNM). Experimental values from Ohtaka
et al.,47 Ohtaka and Freire,48 Velazquez-Campoy et al.,49 and Dierynck et al.50 are also shown (denoted by Expt1, Expt2, and ExptAvg, respectively).
Mean energies are in kcal mol−1. Standard errors are shown in parentheses.
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ΔGGBAssocNM results provide excellent agreement with both the
Expt1 and Expt2 data sets as well as the average results ExptAvg.
In all cases, the MMPBSA variant of the analysis method
outperforms the MMGBSA alternative. Disappointingly, the
inclusion of the free energy of association, ΔGAssoc, alone has no
impact on the quality of the ranking using MMPBSA and makes
only a slight improvement for MMGBSA.
Considering the more widely used analysis methodologies, the
MMPBSA results, including and excluding −TΔSNM, provide
good agreement with both the Expt1 and Expt2 data sets as well
as the average results ExptAvg. MMGBSA without normal
modes performs poorly, but the incorporation of −TΔSNM
renders its performance comparable to MMPBSA without this
contribution. Figure 8 indicates that, when normal modes are not
included in the ranking, the relative binding strength for TPV is
signiﬁcantly underestimated compared to the average exper-
imental values for bothΔGMMPBSA andΔGMMGBSA. The inclusion
of the conﬁgurational entropy corrects this and allows the tight
binding drugs LPV, TPV, and DRV to be diﬀerentiated from
those which are consistently seen to be weaker binders in the two
experimental studies. Furthermore, for this set of ligands, when
normal modes are included in the calculation, we signiﬁcantly
improve the coeﬃcient of determination, r2 (see Table 6),
indicating that the diﬀerentiation between drugs is more
quantitatively accurate. The better performance when comparing
against Expt2 and ExptAvg compared to Expt1 is largely due to
the fact that our results ﬁnd DRV to be notably more tightly
bound than the other drugs, in line with the results of Dierynck et
al.50 As in the case of rs, the results for ΔGPBAssocNM and
ΔGGBAssocNM outperform the other methods, indicating that
there is real value in using ΔGAssoc to evaluate the loss of
translational and rotational freedom from the simulation
trajectory as opposed to using the values produced by normal-
mode analysis.
The recent work of Oehme et al.15 examined the ability of
MMPBSA and MMGBSA to rank a selection of HIV-1 protease
inhibitors (three drugs are common to their work and the present
study) using duplicate simulations with similar trajectory lengths
to our individual replicas. The range of experimental ΔG values
they attempted to evaluate was approximately double that of the
diﬀerence between DRV and IDV in our chosen test set. The
focus of their work was to investigate the impact of ligand
parametrization on the free energy values obtained. They found
that the Hartree−Fock method employing 6-31G** basis
functions, which we have used in this study (chosen because it
was that used to parametrize the rest of the force ﬁeld we
employ), performed particularly poorly; their results produced r2
values with a magnitude of less than 0.01 for ΔGMMPBSA and
ΔGtheor−PB and of 0.60 and 0.50 for ΔGMMGBSA and ΔGtheor−GB,
respectively. Their results are comparable with our results when
we include RTV and AZV. Even given the fact that the diﬀerences
we aimed to detect were much smaller, we signiﬁcantly improved
on all of the performance metrics through the use of our
ensemble approach. It is certainly possible that the choice of
ligand parametrization may alter the characteristics of the free
energy landscape in such a way that diﬀering levels of sampling
are required to correctly converge results. However, it seems
unlikely that so large a diﬀerence is produced that results from
such small numbers of simulations would be reproducible, given
the range of values we obtain in our ensemble studies.
3.3. Bootstrapping Analysis of the Inﬂuence of
Ensemble Size. As with the inﬂuence of simulation length on
the mean, we have used a bootstrap analysis to investigate the
inﬂuence of ensemble size on the Spearman rank coeﬃcient (rs)
using the standard deviation of this value as a bootstrap statistic
(σboot−rs). In this instance, an ensemble containing the relevant
number of replicas was sampled (with replacement) from the 50
replica ensemble for each drug 10 000 times and rs calculated
each time. The standard deviation (σboot−rs) of the rank
coeﬃcients provides an estimate of the error associated with
the rankings obtained. Figure 9 shows the inﬂuence of ensemble
size on the reproducibility of the correlation with the ranking
found in the ExptAvg data set for all methodologies
incorporating MMPBSA. In all cases, it is clear that larger
ensembles make for more reproducible rankings with lower
σboot−rs values. WithMMPBSA alone (ΔGMMPBSA), there are only
minor changes in σboot−rs after approximately 25 replicas. A
greater inﬂuence of larger ensembles is observed in the cases
where normal-mode analysis entropy estimates are incorporated
(bothΔGtheor−PB andΔGPBAssocNM). In both cases, improvements
in the reliability of rankings are to be expected by increasing the
ensemble size up to 50 replicas. Similar results are obtained for
the equivalent MMGBSA based methods and in comparisons
with the values for the individual experimental data sets (graphs
are provided in the Supporting Information).
4. CONCLUSIONS
In the present work, we have assessed the potential of the
MMPBSA and MMGBSA methodologies to produce the kind of
reliable and reproducible predictions of binding aﬃnity that
could be used in drug discovery and personalized medicine
applications. We have found that for seven of the nine FDA-
approved HIV-1 protease inhibitors (amprenavir, darunavir,
indinavir, lopinavir, nelﬁnavir, saquinavir, and tipranavir), these
methodologies work well, reproducing experimental rankings
comparably well to how diﬀerent experiments correlate with one
another.
The two largest ligands in our test set, atazanavir and ritonavir,
are poorly handled by all of the approaches we have applied,
illustrating that the MMPBSA and MMGBSA methodologies
have signiﬁcant limitations in the range of ligands that can be
consistently compared (at least in the case of the HIV-1
protease). Compared to the well ranked ligands, these larger
inhibitors have a greater level of interactions beyond the active
site. Such interactions distort protein geometry and are poorly
handled by the single trajectory approaches which we have
employed here. It remains a signiﬁcant challenge for future work
to obtain converged values of the free energy that account for
these diﬀerences. Our ﬁndings also suggest that the optimal
sampling strategy and the applicability of the methods will
depend strongly on the details of the protein target, with even
Table 5. Spearman Rank Coeﬃcient (rs) for Each of the
Studied Computational Free Energy Methodologies
Compared to the Two Experimental Data Sets and Their
Average
method Expt1 Expt2 ExptAvg
ΔGMMPBSA 0.80 0.71 0.72
ΔGMMGBSA 0.63 0.63 0.60
ΔGtheor−PB 0.73 0.78 0.82
ΔGtheor−GB 0.67 0.74 0.76
ΔGPB−Assoc 0.80 0.71 0.72
ΔGGB−Assoc 0.68 0.68 0.65
ΔGPBAssocNM 0.84 0.91 0.93
ΔGGBAssocNM 0.75 0.90 0.87
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what may be thought of as peripheral residues potentially having
a signiﬁcant impact on the computed binding aﬃnities.
In order that free energy calculations can be further veriﬁed
and validated, it is necessary that it becomes standard practice to
present an analysis of the sampling and convergence properties
of computations, not merely their results. The MMPBSA and
MMGBSA methodologies have diﬀerent convergence proper-
ties, with the latter converging much more quickly and being
comparatively insensitive to the length of replica simulations in
our ensembles. These observations agree with the single
simulation results of Srivastava and Sastry,14 in which greater
simulation length was seen to improve the ability of MMPBSA to
rank ligands but not MMGBSA. However, we observe that there
is greater variability in MMPBSA results as they are extended,
which suggests that some of the beneﬁts of trajectory elongation
observed in that study may have been fortuitous. Furthermore,
Figure 8. Average experimental absolute binding free energies (ΔGExptAvg) of wildtype HIV-1 protease bound to seven inhibitors compared with
theoretical predictions using (a) MMPBSA (ΔGMMPBSA), (b) MMGBSA (ΔGMMGBSA), (c) MMPBSA and normal-mode analysis (ΔGtheor−PB), (d)
MMGBSA and normal-mode analysis (ΔGtheor−GB), (e) MMPBSA with free energy of association and normal-mode analysis (ΔGPBAssocNM), and (f)
MMGBSAwith free energy of association and normal-mode analysis (ΔGGBAssocNM). RTV and ATZ are excluded due to systematic overestimation of the
binding aﬃnity of large ligands. Error bars show the standard errors. The blue line represents a linear regression performed on each data set. Spearman
rank coeﬃcients are given in Table 5. A clear improvement in the rankings is produced upon the inclusion of entropy estimates.
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our work demonstrates that, with suﬃcient sampling, conﬁgura-
tional entropies calculated using normal-mode analysis do exhibit
normal distributions, contrary to our previous observations.16
Obtaining normal distributions required us to sample 25
conformations per nanosecond of trajectory. Surprisingly, we
observe the distribution of average replica free energy
contributions from normal modes to be less broad than that
for either MMPBSA or MMGBSA.
Within the range of ligands that can be consistently treated, we
found that the novel combination of MMPBSA with the
vibrational component of normal mode conﬁgurational entropy
and the free energy of association (as suggested by Swanson et
al.23) provides the best statistical reproduction of experimental
results. This methodology captures both the ranking of the drugs
(as measured by Spearman rank coeﬃcient, rs, with a value of
0.93) and the diﬀerentiation between drugs (coeﬃcient of
determination, r2, value of 0.92) found in the average results of
two experimental data sets. The ranking using MMGBSA
alongside these two additional contributions is also superior to
other combinations we have evaluated. The inclusion of the
computationally inexpensive, but rarely used, free energy of
association methodology enhances the ranking obtained
considerably, and our results suggest that its calculation should
become part of best practice for performing MMPBSA/
MMGBSA based calculation in the future.
Good, if notably less accurate, agreement with experimental
results was obtained from MMPBSA alone and from both
MMPBSA and MMGBSA with normal mode entropy con-
tributions. When the free energy of association is not included in
the calculation, the diﬀerence produced by including conﬁgura-
tional entropy is relatively small. However, the extra computa-
tional eﬀort can still be justiﬁed by the improvement in
coeﬃcient of determination when compared to the average of
the two experimental data sets, which suggests that it better
reproduces the magnitude of binding aﬃnity diﬀerence between
the ligands.
One of the most important factors in the ability to obtain the
rankings we have presented is the use of ensemble simulations.
The values obtained within ensembles of 50 replica simulations
of the same protease−drug complex, diﬀering only in initially
assigned atom velocities, varied by as much as 10 kcal mol−1, a
greater range than that between the best and worst binding FDA-
approved inhibitors. The importance of the extensive level of
sampling required to obtain consistently converged estimates of
binding free energies (irrespective of their accordance with
experimental or “real” values) is perhaps the most striking result
of the present study. We have presented distributions of the
results of all of the free energy computations we have conducted,
and we believe that this should become common practice for all
future computational binding aﬃnity studies. The reproducibility
of the rankings we have obtained is heavily dependent on
ensemble size, with a minimum of 25 replicas being suggested by
bootstrapping analysis necessary to provide reproducible results.
We hope that future work will provide standards that better allow
comparisons of diﬀerent studies using a range of techniques and
simulation parameters.
The aim of this study has been not only to validate the ability of
MMPB(GB)SA-based free energy calculations to distinguish
HIV-1 protease inhibitors but to investigate the broader
suitability of the methods for rational drug design and
personalized medicine applications. One of the major attractions
of MMPB(GB)SA calculations is the promise of general
applicability to any chemical species, whereas other techniques,
such as free energy perturbation (FEP) or thermodynamic
integration (TI), are practically limited to considering free
energy diﬀerences between molecules that are relatively similar.
Table 6. Coeﬃcient of Determination (r2) for Each of the
Studied Computational Free Energy Methodologies
Compared to the Two Experimental Data Sets and Their
Average
method Expt1 Expt2 ExptAvg
ΔGMMPBSA 0.71 0.39 0.64
ΔGMMGBSA 0.48 0.26 0.44
ΔGtheor−PB 0.58 0.74 0.77
ΔGtheor−GB 0.61 0.76 0.83
ΔGPB−Assoc 0.74 0.41 0.67
ΔGGB−Assoc 0.52 0.28 0.48
ΔGPBAssocNM 0.66 0.86 0.92
ΔGGBAssocNM 0.59 0.77 0.84
Figure 9. The variation of the bootstrap statistics, σboot−rs, with the
number of replicas within an ensemble on the Spearman rank coeﬃcient
(rs) for the ranking of the seven FDA-approved inhibitors for which our
methodologies are valid against the average experimental data set
(ExptAvg) using (a) MMPBSA alone (ΔGMMPBSA), (b) MMPBSA and
normal-mode analysis (ΔGtheor−PB), and (c) MMPBSA normal-mode
analysis and the free energy of association (ΔGPBAssocNM). In all cases, the
variation in the ranking is seen to reduce with the number of replicas up
to 50, although the decrease slows after 20 to 25 replicas are included in
the ensemble.
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In drug discovery and lead enrichment applications, the task is to
provide rapid results for libraries of hundreds or thousands of
candidate compounds. The computational cost of the ensemble
MD simulations that we found necessary to obtain reliable
MMPB(GB)SA values means that at present the use of these
techniques in this ﬁeld is unsuitable. It is likely that, for such
applications, empirical scoring functions based on quantitative
structure−activity relationship (QSAR) models will continue to
be the best option (despite the obvious dangers of extrapolating
beyond the data used to derive them). In personalized medicine
contexts, the demands are however quite diﬀerent, with results
typically required only for a limited selection of drugs bound to
one or a few target protein sequences. We have previously shown
how MD simulations could be integrated into clinical decision
support systems as part of the ViroLab project.17,55 Furthermore,
the required turnaround times of days or up to a week are easily
realizable. Ensemble simulations represent a very time-eﬃcient
method of performing MD calculations, as each replica can be
run concurrently given suﬃcient computer resources. The 6 ns of
trajectory for each replica can typically be produced in 15 h
(assuming 2.5 h per nanosecond using 64 CPU cores based on
our experience on several machines) and the free energy analysis
within another 12 h. These times are only likely to reduce as new
technology is introduced and algorithmic improvements are
implemented.
Combining the results for diﬀerent inhibitors presented here
with our previous demonstration that the MMPBSA method-
ology with normal modes can successfully and reproducibly
estimate the binding aﬃnities of mutant proteases to a single
inhibitor,16 we believe that MMPB(GB)SA techniques are
capable of making signiﬁcant contributions in academic research
as well as basic and clinical medicine.
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